Reduced Glutamine Content in Colonic Polyps

Goldin, Ehud; Aptekar, L.; Siguencia, J.; Tsvang, E.; Fich, Alexander; Zimmerman, Joseph

doi:10.3109/00365529609006408

Cited by 5 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher glutaminase activities were found in human intestine than in colon tissues (38). In colonic polyps, GLN content and glutaminase activities were lower than in normal-paired tissues (39). Our results suggested that the transcriptional levels of each isoform may be regulated differently in the presence of GLN.…”

Section: Discussionmentioning

confidence: 56%

Expression of PPARγ is reduced by medium supplementation with L-glutamine in human colorectal Caco-2 cells

Fiatte¹,

Huin²,

Collet³

et al. 1998

Int J Mol Med

View full text Add to dashboard Cite

Abstract. Peroxisome proliferator-activated receptor-γ (PPARγ) belongs to the nuclear hormone receptor family. This receptor is implicated in colon cell differentiation and in colon cancer. Receptor activation by specific agonists has been shown to protect against colon cancer progression. PPARγ protein content within cells is modulated by several mechanisms, including proteasome degradation, activation of Wnt signalling pathways and presence of fermentation products such as butyrate. Herein, we investigated the impact of L-glutamine on PPARγ expression during the differentiation of Caco-2 cells grown in medium containing dialyzed fetal calf serum supplemented or not with L-glutamine. Using RT-PCR and Western blotting, we demonstrated that PPARγ expression was decreased when L-glutamine was added to the medium. Using immunohistochemistry, we demonstrated that PPARγ immunostaining was mainly found in cytoplasm when cells were cultured with L-glutamine while it was found in nuclei and cytoplasm when cells were grown without the addition of L-glutamine. Supershift retardation assays demonstrated a decrease of PPARγ binding onto consensus peroxisome proliferator response element. We concluded that L-glutamine modulated PPARγ expression in Caco-2 cells.

show abstract

Section: Discussionmentioning

confidence: 56%

Expression of PPARγ is reduced by medium supplementation with L-glutamine in human colorectal Caco-2 cells

Fiatte¹,

Huin²,

Collet³

et al. 1998

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…It has two nitrogen groups in side chains that act as the most important transporter of circulating nitrogen. [ 14 20 ] Therefore, its supplementation affects nitrogen balance and increase retain of nitrogen, because of the quantity of nitrogen provided by Gln. [ 16 17 ]…”

Section: Discussionmentioning

confidence: 99%

“…[ 12 45 ] It has been illustrated that Gln consumption increases in tumor tissues and consequently decreases its concentration. [ 14 ] Hence, it is possible that Gln feeding can help to high gastrointestinal tract tumor cell turnover that it may lead to more growth of these cells. [ 52 53 ]…”

Section: Discussionmentioning

confidence: 99%

“…[ 12 13 ] Furthermore, this nutrient is considered as an essential amino acid conditionally and its requirement increases in catabolic diseases including cancers. [ 14 15 16 ] Also, it was observed that Gln depletion among patients with colorectal cancer can lead to suppression of the T-cell response. Therefore, the immune system cannot destroy the cancer cells in this situation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of glutamine intake on complications of colorectal and colon cancer treatment: A systematic review

Jolfaie

Mirzaie

Ghiasvand³

et al. 2015

J Res Med Sci

View full text Add to dashboard Cite

Background:Improvement in complications of antitumor agents and surgery is important to enhance life quality and survival among patients with colon and colorectal cancer. It has been reported that some dietary components such as glutamine (Gln) have beneficial effects on these complications of cancer therapies. However, the results of studies are inconsistent in this area. We performed a review on randomized controlled trials (RCTs) evaluating the effects of Gln intake on complications related to therapeutic strategies of the colon and colorectal cancer.Materials and Methods:A systematic search was conducted in PubMed, Google Scholar, Cochrane Library, and SID databases to find the relevant literature, published before July 2015.Results:Nine RCTs of 217 screened articles were included in this systematic review. The results of the present review suggested that Gln intake among colon and colorectal cancer patients could reduce some complications induced by chemotherapy such as gut mucositis and diarrhea and improve nitrogen balance, immune system and wound healing after surgery, whereas benefits role of Gln on radiochemotherapy side effects were not provided.Conclusion:The role of Gln intake on some improvement of complications induced by cancer therapeutic methods and shorten the length of hospital stay may be promising and one that is worthy of further exploration.

show abstract

Auswirkungen der Restaurativen Proktokolektomie auf den Glutaminstoffwechsel bei Patienten mit Colitis Ulcerosa und Patienten mit Familiärer Polyposis Coli

Allemeyer

Hinz

Heuschen

et al. 2001

Deutsche Gesellschaft Für Chirurgie

View full text Add to dashboard Cite

Reduced Glutamine Content in Colonic Polyps

Abstract: Adenomatous polyps might behave as a glutamine trap, channeling glutamine to protein and nucleic acid synthesis. These changes in glutamine catabolism could play a role in colonic neoplasia pathogenesis.

Cited by 5 publications

References 12 publications

Expression of PPARγ is reduced by medium supplementation with L-glutamine in human colorectal Caco-2 cells

Expression of PPARγ is reduced by medium supplementation with L-glutamine in human colorectal Caco-2 cells

The effect of glutamine intake on complications of colorectal and colon cancer treatment: A systematic review

Auswirkungen der Restaurativen Proktokolektomie auf den Glutaminstoffwechsel bei Patienten mit Colitis Ulcerosa und Patienten mit Familiärer Polyposis Coli

Contact Info

Product

Resources

About